Honeybro Pharmaceutical Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 9 Year, 4 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 1.25 M
- Revenue Growth -25.73%
- Profit Growth -29.73%
- Ebitda -24.56%
- Net Worth 22.46%
- Total Assets -12.48%
About Honeybro Pharmaceutical
Honeybro Pharmaceutical Private Limited (HPPL) is a registered startup operating as a Private Limited Indian Non-Government Company incorporated in India on 23 September 2015 (Nine years and four months 18 days old ). Its registered office is in Pune, Maharashtra, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹1.25 M.
Sunanda Patri and Shantiling Patri serve as directors at the Company.
Company Details
-
Location
Pune, Maharashtra, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U24233PN2015PTC156546
-
Company No.
156546
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
23 Sep 2015
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Pune
Industry
Who are the key members and board of directors at Honeybro Pharmaceutical?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sunanda Patri
|
Director | 23-Sep-2015 | Current |
|
Shantiling Patri
|
Director | 23-Sep-2015 | Current |
Financial Performance of Honeybro Pharmaceutical.
Honeybro Pharmaceutical Private Limited, for the financial year ended 2021, experienced significant reduction in revenue, with a 25.73% decrease. The company also saw a substantial fall in profitability, with a 29.73% decrease in profit. The company's net worth Soared by an impressive increase of 22.46%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Honeybro Pharmaceutical?
In 2021, Honeybro Pharmaceutical had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Bask-Ray India Private LimitedShantiling Patri is a mutual person
Charges (Loans)
₹1.25 M
₹0
Charges Breakdown by Lending Institutions
- Hdfc Bank Limited : 0.12 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 19 May 2023 | Hdfc Bank Limited | ₹1.25 M | Open |
How Many Employees Work at Honeybro Pharmaceutical?
Unlock and access historical data on people associated with Honeybro Pharmaceutical, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Honeybro Pharmaceutical, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Honeybro Pharmaceutical's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.